Two New Appointments at Meditor Pharmaceuticals Ltd.
Posted on: Monday, 12 May 2008, 18:00 CDT
REHOVOT, Israel, May 12 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today the appointment of Prof. Arie Schachner to serve as a Senior Medical Advisor to the company.
Dr. Schachner has been a member of Meditor's Scientific Advisory Board since 2001 and will now take a more active role in the Clinical Development program.
Prof. Schachner was the founder and Head of the Cardiac Surgery Department at Wolfson Medical Center and Tel Aviv University Sackler Medical School. He is an opinion leader in the Cardiac Surgery area, he is a distinguished member of several professional societies and has many publications in this field. Prof. Schachner will collaborate with recently appointed CEO, Dr. Adrian Harel, in the ongoing Phase II Clinical trial on Hypotension in patients undergoing Cardio Artery Bypass Graft (CABG) patients and in designing future clinical trials.
Dr. Adrian Harel joined Meditor in January 2008. He combines a broad scientific education with extensive industry experience. He holds a Ph.D. in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug research & development know-how and GMP production and manufacturing knowledge.
About Meditor Pharmaceuticals: Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a unique low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the treatment of three main medical targets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106 (immediate release oral tablet formulation) for Migraine, and MTR105 (i.v. formulation) for the treatment of hypotension associated with cardiac surgery. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit http://www.meditorpharma.com/
For all inquiries please contact Mr. Rafi Barkan, Chairman at +972 8 930 3307 or Dr. Adrian Harel, CEO at +972 8 930 3305.
Meditor Pharmaceuticals Ltd.
CONTACT: Mr. Rafi Barkan, Chairman, +972 8 930 3307; or Dr. AdrianHarel, CEO, +972 8 930 3305, both of Meditor Pharmaceuticals Ltd.
Web site: http://www.meditorpharma.com/
Source: PRNewswire
Related Articles
- Photo Release -- Lindora Medical Clinics Roll Out Product Line At Select Rite Aid Locations
- Southwestern Medical Clinic to Use Allscripts EHR
- Premera and Pike Market Medical Clinic Announce Multi-Year Collaboration to Provide Medical Care to Downtown Seattle's Poor
- Winn-Dixie Partners With WELLSPOT Medical Clinics To Bring Affordable Medical Care to Customers
- Dallas Gets Its First Retail Medical Clinic As MedXpress Opens in New Carnival Super Store; In-Store Clinic Provides Fast, Convenient Affordable Health Care
- Storefront Medical Clinics: Cheap and Fast
- Atherotech's VAP(R) Test Now Exclusive Method of Cholesterol Measurement at Lindora Medical Clinics; Blood Test Detects Hidden Heart Disease Risk and the Metabolic Syndrome
- Low Cost, Convenience Drive in-Store Medical Clinic Trend
- Northwest Florida Medical Clinics Fill the Void From Katrina
- Riverside Medical Clinic Begins Construction on $27 Million Patient Care Building
 |
 |
User Comments (0)
RSS Feeds